Want to see BMRA full AI Analyst Report?
BMRA Stock Chart & Stats
$2.88
-$0.02(-5.81%)
At close: 4:00 PM EST
$2.88
-$0.02(-5.81%)
Day’s Range― - ―
52-Week Range$1.61 - $4.60
Previous CloseN/A
Volume74.49K
Average Volume (3M)190.48K
Market Cap
$4.99M
Enterprise Value$4.94M
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)$193.00K
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding3,090,269
10 Day Avg. Volume453,881
30 Day Avg. Volume190,481
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.71
Price to Sales (P/S)1.32
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit26.44
Enterprise Value/Ebitda-1.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageBiomerica’s minimal total debt and ~0.06 D/E provide durable financial flexibility versus higher-leverage peers. Low leverage reduces near-term refinancing and solvency risk, giving management time to address operational deficits and pursue selective investments without immediate creditor pressure.
Diversified DistributionA mix of direct sales, third-party distributors and international partners creates multiple scalable go-to-market channels. This reduces customer concentration risk, supports incremental geographic expansion, and enhances the firm's ability to grow revenue when product adoption or pricing improves.
Related-party Liquidity BridgeThe $500k advance structured as a secured note tied to Diagnosis shares provides an immediate, contractually backed liquidity buffer. That bridge materially extends runway in the near term, reducing the urgency for emergency capital and allowing time to execute operational recovery steps.
Bears Say
Declining Revenue & Low MarginsTop-line weakness and a ~4% gross margin severely limit the company's ability to cover fixed costs and generate operating leverage. Structural improvement requires either materially higher volumes, improved pricing, or significant cost-of-goods reductions to reach sustainable profitability.
Persistent Cash BurnConsistent negative operating and free cash flow (TTM ~-$3.2M) forces ongoing reliance on external financing. Persistent burn constrains reinvestment in commercial initiatives, increases financing cost exposure, and makes the business structurally vulnerable to funding interruptions.
Shrinking Equity BaseA materially eroded equity base reduces the balance-sheet cushion against further losses and weakens the company’s capacity to absorb shocks. Lower equity heightens the probability of dilutive financings and limits access to non-dilutive capital, undermining long-term stability.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.61 and its highest was $4.60 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $4.99M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Aug 27, 2026 which is in 38 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Apr 13, 2026. The company reported -$0.436 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.436.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 3,090,269 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.436 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.962%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
13.18% Insiders
6.66% Mutual Funds
0.03% Other Institutional Investors
79.66% Public Companies and
Individual Investors